|
TET2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.80630000004667E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.362700E-04 |
| Normal-vs-Stage2 |
1.5197799999922E-05 |
| Normal-vs-Stage3 |
2.09990000055171E-07 |
| Normal-vs-Stage4 |
1.33319999995329E-06 |
| Stage1-vs-Stage2 |
4.801600E-02 |
| Stage1-vs-Stage3 |
1.278430E-02 |
| Stage1-vs-Stage4 |
1.194170E-02 |
| Stage2-vs-Stage3 |
8.695200E-01 |
| Stage2-vs-Stage4 |
9.436200E-01 |
| Stage3-vs-Stage4 |
8.013200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.47359999999897E-06 |
| Normal-vs-AfricanAmerican |
9.253900E-02 |
| Normal-vs-Asian |
5.960800E-04 |
| Caucasian-vs-AfricanAmerican |
2.439000E-01 |
| Caucasian-vs-Asian |
9.910000E-01 |
| AfricanAmerican-vs-Asian |
3.109200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.167700E-04 |
| Normal-vs-Female |
2.38689999998432E-06 |
| Male-vs-Female |
6.057000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.723100E-03 |
| Normal-vs-Age(41-60Yrs) |
1.05360000002275E-06 |
| Normal-vs-Age(61-80Yrs) |
3.52229999944775E-07 |
| Normal-vs-Age(81-100Yrs) |
9.175000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.839970E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.702700E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.498800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.058600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.398400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.711400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.719400E-03 |
| Classical-VS-Follicular |
5.901800E-03 |
| Classical-VS-Other |
7.541600E-01 |
| Classical-VS-Normal |
4.622000E-04 |
| Tall-VS-Follicular |
4.048000E-01 |
| Tall-VS-Other |
2.247800E-01 |
| Tall-VS-Normal |
2.21129999999903E-06 |
| Follicular-VS-Other |
5.676600E-01 |
| Follicular-VS-Normal |
2.47880000003864E-06 |
| Other-VS-Normal |
9.716200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.06779999995166E-06 |
| Normal-vs-N1 |
1.555490E-04 |
| N0-vs-N1 |
9.749400E-01 |
|
|
